

AutoPhagyGO

BUSINESS PLAN 2026–2030

Building a Data-Driven Longevity Platform
Powered by Autophagy Science


Miwako Ishido, Ph.D.
Representative Director & CEO

Overcoming Aging Through Autophagy

OUR CORPORATE VISION

BUILDING JAPAN LONGEVITY ECOSYSTEM

From World-Class Autophagy Science to a Data-Driven Longevity Platform



APGO builds the **Japan platform**.

A **US-based NewCo** connects it to US capital, innovation and global markets.

Why Now

LONGEVITY IS MOVING BEYOND MEASUREMENT

The value is shifting from generating a test result to continuously learning what improves Healthspan.



AUTOPHAGY: A KEY BIOLOGICAL MECHANISM OF AGING

Recognized as a hallmark of aging and a critical driver of cellular quality control, proteostasis, and mitochondrial health — central to healthy aging and longevity.

From basic biology to a measurable and actionable longevity target

TRADITIONAL MODEL

Test → Diagnose

Episodic / disease-oriented



TEST

Single point measurement



DIAGNOSE

Snapshot result & limited insight

One-time | Reactive | Limited context



EMERGING LONGEVITY MODEL

Measure → Understand → Act → Learn

Continuous / personalized / data-driven



MEASURE

Continuous data collection

Biomarkers, wearables, lifestyle, clinical data, and more



UNDERSTAND

Multi-dimensional insight & AI analysis

Biological age, risk, patterns, and root drivers



ACT

Personalized interventions

Nutrition, exercise, supplements, meds, mindset, and more



LEARN

Outcome feedback & continuous improvement

Re-measure, evaluate outcomes, and refine the next action

Continuous learning cycle

ACCELERATED BY
AI / DATA
The engine powering the longevity cycle



Massive Data

From individuals, devices, clinics, and partners



AI & Machine Learning

Discover patterns, predict outcomes, personalize actions



Real-world Evidence

Continuously improving solutions and interventions




Scalable Impact

Better healthspan for more people, faster

Why Japan & the Capital / Innovation GAP


Japan is the Leading Longevity Growth Market.

The US has the Capital and Innovation.



What's the Problem?

We are measuring more than ever – but not yet measuring what matters enough to act.



The Desired Future

Measure autophagy. Understand deeply. Act precisely. Learn continuously.

A virtuous cycle for healthy longevity.



Autophagy measurement becomes a core part of everyday health management—powering a virtuous cycle of understanding, action, and continuous improvement.

WHY APGO: Science x Execution x Ecosystem

APGO brings together world-class science, proven execution, and a powerful ecosystem to build the global longevity platform.

SCIENCE

Japan leads the world in autophagy research.

A scientific legacy that begins with discovery and continues in human biology and aging.



Direct lineage from Japan's world-leading autophagy research

Founded by Prof. Tamotsu Yoshimori, a pioneer of mammalian autophagy research and global leader in the field.



Prof. Tamotsu Yoshimori
APGO Founder



Proprietary assays & know-how

tfLC3, Rubicon, platelet LC3-II and other high-sensitivity biomarkers protected by IP and deep know-how.



Autophagy x Aging Biology

Decades of research linking autophagy regulation to aging, disease and healthspan. Recognized as a core biological mechanism of aging.



Deep mechanistic expertise

From molecular mechanisms to cellular, organismal and human biology. Rigorous protocols, reference labs, capabilities, and scientific credibility.



ECOSYSTEM

Strong ecosystem and market access in Japan and globally.



40+ clients and growing

Pharma, biotech, healthcare, food, and consumer industries



Commercial traction

Proven demand for autophagy measurement and solutions



Strategic partnerships

Dentsu (marketing & branding), Curations (EC & distribution), and more



Expanding ecosystem

CELLED (digital/clinic solutions)
AutoPhagyRUN (China & Asia business) and other partners

From Science to Real-World Traction

APGO has already built and commercialized the core capabilities behind the platform



40+
CLIENTS

Pharma, biotech, food, healthcare,
cosmetics, and digital health



CELL → HUMAN
MEASUREMENT

The only company enabling autophagy
measurement from cells to humans
with industrial-level throughput
and reproducibility



PRIZE™
TOP 40
XPRIZE HEALTHSPAN

Selected as Top 40 teams worldwide
in the XPRIZE Healthspan competition
(2024–2025)






2,500 / MONTH*
PRODUCT SALES

AWABANCHA AUTOPHAGY 100
Sales growth to approx. 2,500 units / month
as of May 2026

*Monthly sales as of May 2026

1. MEASURE (From Cells)

Proprietary autophagy measurement
technology



- tfLC3 assay
- High-throughput system
- Platelet LC3-II Flux
- Serum Rubicon

Highly sensitive, quantitative, and
reproducible assays across multiple
biospecimens and platforms

2. VALIDATE (In Humans)

Human intervention studies
and real-world evidence



TOP 40
2024–2025



- ✓ Randomized, controlled human trials
- ✓ Autophagy activation linked to physical & biological improvements
- ✓ Multi-omics, biomarkers, and real-world outcomes

Building the largest Japan-based
autophagy human dataset

3. COMMERCIALIZE (Products)

From science to consumer products

**AWABANCHA
AUTOPHAGY
100**



Launched in 2025

**AWABANCHA
AUTOPHAGY
400+**




Launched in 2026
(Clinic exclusive)


Powered by Awa-Bancha (unique
post-fermented tea) × Autophagy science

4. MARKET TRACTION (Sales & Media)

Sales growth of
AWABANCHA AUTOPHAGY 100



Media & Demand



- Nationwide media coverage
- Strong consumer demand
- Frequent stock-outs

Science → Media → Demand → Sales
A proven execution engine

Beachhead: Autophagy Measurement

From measurement to solutions, then Japan to the world.

AUTOPHAGY MEASUREMENT



CELL-BASED ASSAYS

- Contract testing
- Drug discovery
- Food screening



HUMAN ASSAYS

- tflLC3 (phosphorylated LC3)
- Rubicon (ELISA)
- Platelet LC3-II flux assay



CLINICAL MEASUREMENT

- Clinical studies & trials
- Biomarker evaluation
- CRO / investigator support

Already commercialized

SOLUTIONS FOR HEALTHSPAN

APGO OWNED PRODUCTS Awa Bancha Supplement



- Proprietary fermentation
- Activates autophagy
- Commercialized in Japan

DIGITAL / CLINIC SOLUTIONS



CELLED

- Digital platform for clinics & users
- Personalized interventions
- Data analytics & insights
- Behavior change support

Already in market

US INNOVATION → JAPAN MARKET



GLOBAL INNOVATION PARTNERS

- Longevity startups
- Biomarkers / technologies
- Digital health solutions
- Nutraceutical ingredients



NewCo (US / Global)

Global Business Development & Market Access

- Source & evaluate innovations
- Global partnerships & licensing
- Regulatory & market access
- Bring solutions to Japan

Acting as the bridge to Japan



JAPAN-PROVEN MODEL → US / GLOBAL IMPACT



APGO PLATFORM


- Proprietary assays & IP
- Human biological data
- Longevity intelligence



NewCo (US / Global) Global Expansion Hub

- US / Europe / Other markets
- Global commercialization
- Capital & strategic partnerships
- Cross-border distribution

Scale to the aging world



HUMAN BIOLOGICAL DATA



- People (diverse cohorts)
- Interventions (products, programs, lifestyle)
- Outcomes (health, function, biomarkers)



LONGEVITY INTELLIGENCE

AI-driven insights to understand what works, for whom, and why

- Predict response
- Optimize interventions
- Improve healthspan and extend healthy life

EXPANDS BEYOND AUTOPHAGY



Other biomarkers
Integrate additional biomarkers and multi-omics



Health & lifestyle data
Wearables, behavior, environment, and lifestyle data




Partner data
Combine with partner and public datasets to accelerate discovery & validation



Global data network
Build a global autophagy data ecosystem


Business Model & Ecosystem Structure

APGO Science Powers the Platform. NewCo Scales the Business.



APGO & NewCo: Clear Roles, Shared Flywheel


APGO owns the science. NewCo scales the intelligence and solutions.



APGO develops and owns the science and measurement assets.
NewCo scales them into a global platform that delivers real impact.

Globalization Strategy

US ↔ JAPAN: NewCo is the Gateway. From Japan-Proven Model to Global Impact.



CELLED
Digital & Clinic Solutions

Builds and operates digital & clinic solutions:
 Digital platform & mobile app / Clinic operations & UX /
 Digital interventions / Behavioral data framework



APGO provides the science, data and Japan platform.
NewCo (US-based) commercializes, partners, raises capital and expands businesses globally.

NewCo (US)

Does not build digital or clinic solutions.
 Focuses on commercialization, partnerships, capital raising and global expansion from the US.

Platform MOAT & Flywheel

A self-reinforcing cycle that creates durable competitive advantages and accelerates growth



Roadmap & fundraise

From Autophagy Science to a Global Longevity Intelligence Platform

	2026–27 Phase 1 Build Japan Platform + Launch US NewCo	2028–29 Phase 2 Connect US Innovation with Japan / Build US Commercial Base	2030+ Phase 3 Scale Japan-Proven Platform Globally through US NewCo
 TECHNOLOGY	APGO: Japan platform / science / data / validation • tLC3 + Rubicon / LC3-II • Human biomarker discovery & validation • Biomarker panel development • Autophagy as mechanistic anchor • Multi-layer aging data integration NewCo (US): US incorporation / US-resident team / US VC raise / US BD	• Cross-lab validation in Japan & the US • Selected US technologies transferred to Japan • Composite score development • Multimodal intervention & response models • Biological state profiling & trajectory modeling	• Multi-marker platform scaled globally • Intervention-response analytics platform • Regulatory optionality & global strategy • AI-driven intervention intelligence • Continuous learning from real-world data
 CUSTOMERS	APGO: Japan market access & early adoption • Existing clients & research partners • Clinical Trial Package (Japan) • Longevity / pharma pilots in Japan • Preventive health & lifestyle data collection NewCo (US): US BD foundation & network building Investor & customer outreach in the US	• Pharma / longevity trials (Japan + US) • Overseas KOL & CRO adoption • Repeat multi-market use cases • Enrich dataset with outcomes & interventions • US customer pilots & early commercial adoption	• Global trial adoption • Certified lab customers worldwide • Data / analytics users (Pharma, Payers, Platforms) • Partners across therapeutics, diagnostics, digital health & wellness • Broader consumer engagement
 GLOBAL	• Japan Reference Lab • Overseas KOL relationships • Partner-lab selection in US / EU / Asia	• US / EU / Asia partner labs & alliances • Technology transfer & joint studies • Certification framework alignment • Regional data hubs & interoperability	• Certified Global Lab Network • Distributed measurement & standards • Standardized data & reference database • Global regulatory alignment
 FUNDRAISE (Led by NewCo*)	Seed / Series A \$10–20M Fundraise US team build • US validation • platform development global market development FUNDRAISE (Led by NewCo*) Series B (TBD) (Amount TBD) US commercial base build • partnerships • scale Japan–US collaboration Series C+ (TBD) (Amount TBD) Global scale through US NewCo and partner network expansion		

Our AutoPhagyGO Team



Tamotsu Yoshimori, Ph.D.

Founder



Miwako Ishido, Ph.D.
CEO



Kazushige Hirayama
CFO



Yosuke Suzuki, MBA
CSO



Company Profile

Company Name	AutoPhagyGO Inc.
Founder	Tamotsu Yoshimori
CEO	Miwako Ishido
Founding year	2019
Location	The University of Osaka (Suita campus)
Total funding	532,860,000 JPY
Company stage	Early
Origin	The University of Osaka
URL	https://autophagygo.com/
Vision	Empowering Healthy Longevity through Autophagy.
Business overview	Contract and collaborative research, product development, and drug discovery related to autophagy, based on our proprietary and precise autophagy activity measurement technology.
Service	Autophagy activity contract measurement services, collaborative research related to autophagy, development and sales of autophagy-related supplements and cosmetics, and autophagy-based drug discovery.
Competitive advantage	The only company that enables autophagy activity measurement from cells to humans with industrial-level throughput and reproducibility.
Market size	Biohacking Products and Devices Market: USD 24.5 B (2024) → USD 111 B (2034)Source: Research and Markets
Major partners	UHA Mikakuto Co., Ltd. Human Metabolome Technologies, Inc. Dentsu Inc. Curations Inc.

